Abstract:Objective:To observe the adverse reactions caused by different doses of N-acetylcysteine(NAC) in treatment of patients with severe liver diseases for an approach to the drug safe use.Methods:Between February 2006 and January 2008,173 patients with various patterns of severe liver diseases in our hospital were enrolled in the study.One hundred and seventy-three patients were divided into 3 groups:the high-dose group(25 cases),the low-dose group(66 cases),and the dose-escalation group(82 cases).The high-dose group comprised 16 men and 9 women with average age(42.3±3.6) years.The low-dose group comprised 42 men and 24 women with average age(41.6±4.8) years.The dose-escalation group comprised 51 men and 31 women with average age(45.2±5.2) years.The drug administration was as follows:the patients in the high-dose group were administered an IV infusion of NAC 8 g dissolved in 10% glucose 250 ml once daily;the patients in the low-dose group were administered NAC 4 g dissolved in 10% glucose 250 ml once daily,while oral famotidine 20 mg twice daily and slowly IV push of 10% calcium gluconate 10 ml mixed with 50% glucose 20 ml were given.The patients in the dose-escalation group received an initial dose of IV NAC 4 g/d,and if no adverse reaction occurred,the dose of NAC was increased to 8 g/d on day 4.The administration and other medications were the same as those in the low-dose group.All patients were observed at least two weeks.Results:In the high-dose group,adverse reactions occurred in 16 cases(64%) of 25 patients including 9 cases(36%) of skin disorders,2 cases(8%) of chest distress and dizziness,3 cases(12%) of gastrointestinal disorders,one case(4%) of anaphylactic shock,and one case(4%) of lower limbs dyskinesia.The Model for End-Stage Liver Disease(MELD) scores to the patients experiencing adverse reactions and the patients no experiencing adverse reactions in the high-dose group were 11.26±5.47 and 18.38±5.71,respectively.The difference was statistically significant(P<0.05).It indicated that the condition of patients experiencing adverse reactions was mild.In the low-dose group,adverse reactions occurred in 2 cases(3.03%) of 66 patients including 1 case of rash,and 1 case of upper abdominal discomfort.The incidence of adverse reactions in the low-dose group was lower than that in the high-dose group.The difference was statistically significant(P<0.001).The MELD scores in the patients experiencing rash and the patients experiencing upper abdominal discomfort were 11.38 and 10.29,respectively.In the dose-escalation group,4 patients(4.88%) developed adverse reactions within 3 days of treatment;seven(8.97%) of other 78 patients developed adverse reactions in more than 4 days of treatment,and the incidence was higher than the low-dose group and lower than the high-dose group(all P<0.001).Of the 78 patients,31 patients'MELD score was >15,and one case of gastrointestinal disorders and one case of skin rash occurred;47 patients'MELD score was <15,and 3 case of gastrointestinal disorder,one case of scalp swelling and one case of skin rash occurred.The difference between both of them was statistically significant(P< 0.001).The patients'adverse reactions disappeared after discontinuation of the drug and symptomatic treatment.Conclusion:Low-dose or dose-escalation NAC combined with oral famotidine and IV calcium gluconate 10% is a safe regimen in treatment of severe liver diseases,but relatively mild cases of severe liver diseases should be closely monitored during treatment in order to avoid or decrease adverse reaction occurring.

A Multi-Center Clinical Prospective Study of N-acetylcysteine on Severe Hepatic Disease

Study on clinical safety of different doses of N-acetylcysteine in treatment of patients with severe liver diseases

The effect of histone deacetylase inhibitor ACY1215 on the inflammatory response in mice with acute liver failure

Protective effect of histone deacetylase inhibitor ACY1215 on hepatocyte mitochondria in rats with acute hepatic failure

Retrospective Analysis of the Clinical Efficacy of N-Acetylcysteine in the Treatment of Hepatitis B Virus Related Acute-on-Chronic Liver Failure

Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis.

A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life

Protection of N-acetylcysteine on alcoholic liver injury rats

A Clinical Study on the Treatment of Severe Hepatitis by a Combined Artificial Liver.

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

N-acetylcysteine for non-acetaminophen induced acute liver failure: A review

Clinical Research for Application of N-acetylcysteine in Children with Pneumonia and SIRS

Comparing the Therapeutic Effectiveness of N-acetylcysteine with the Combination of N-acetyl Cysteine and Cimetidine in Acute Acetaminophen Toxicity: A Double-Blinded Clinical Trial

[Aspartate-Ornithine Granules in the Treatment of Nonalcoholic Steatohepatitis: a Multiple-Dose Parallel Controlled Clinical Trial].

Effects of aerosolized inhalation of N-acetylcysteine combined with high flow nasal cannulae oxygen therapy on inflammation, oxidative stress, and cognitive function in patients with severe pulmonary infection complicated with respiratory failure

Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease

N-acetylcysteine Clinical Applications

N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review

Effects of N-Acetylcysteine combined with Ambroxol Hydrochloride on clinical symptoms, CRP, and PCT in children with pneumonia

Effects of N-acetylcysteine on hepatocellular carcinoma in chronic hepatitis C

N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review